News
US approval for Boehringer Ingelheim, Lilly’s heart failure drug Jardiance
Jardiance (empagliflozin) has been approved by the US Food and Drug Administration (FDA) to reduce the risk of cardiovascular death plus hospitalisation for adults with heart failure with reduced ejection fraction (HFrEF).